No­var­tis records an­oth­er tislelizum­ab win en route to bring­ing BeiGene's PD-1 to FDA's doors

4 years ago
R&D
China

Am­gen kicks back I/O drug at cen­ter of $500M deal, leav­ing biotech part­ner alone to pon­der next steps

4 years ago
Deals

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

4 years ago
People
Discovery

Scoop: Bridge­Bio's chief strat­e­gy of­fi­cer re­signs as the com­pa­ny qui­et­ly em­barks on an­oth­er round of lay­offs

4 years ago
R&D

CDER di­rec­tor on ac­cel­er­at­ed ap­proval re­forms and a court de­ci­sion that will 'send a chill' across rare dis­ease drug ...

4 years ago
FDA+

States may need to tweak gener­ic drug laws to in­crease ac­cess, re­searchers find

4 years ago
Pharma

Sanofi of­floads French rights for an­tipsy­chot­ic to neigh­bor­ing phar­ma

4 years ago
Deals
Pharma

NYU con­sid­ers hir­ing for­mer MIT sci­en­tist David Saba­ti­ni af­ter sex­u­al ha­rass­ment probe — re­port

4 years ago
People
Pharma

Sanofi en­lists an F1 rac­ing team to help op­ti­mize its man­u­fac­tur­ing op­er­a­tions

4 years ago
Pharma
Manufacturing

Vi­iV, Pfiz­er and Roche lead list for phar­ma rep­u­ta­tion ranked by pa­tient group, an­nu­al sur­vey finds

4 years ago
Pharma
Marketing

Malaysian gov­ern­ment en­lists na­tive Bio­con for in­sulin sup­ply deal

4 years ago
Manufacturing

Thou­sands of jobs are on the chop­ping block as No­var­tis lays out re­struc­tur­ing plans, M&A hunt for deals up to $2B

4 years ago
Pharma

Mar­ket­ingRx roundup: Bio­Marin de­buts film work­shop for peo­ple with he­mo­phil­ia; J&J re­ups 'Y­ou Be­long' di­ver­si­ty push

4 years ago
Pharma
Marketing

The pod peo­ple of phar­ma: Pod­cast vet­er­ans and new­bies di­al up con­ver­sa­tion­al sci­ence, en­ter­tain­ment and brand ...

4 years ago
Pharma
Marketing

Irv Weiss­man­'s lab spins out an­oth­er biotech, with help of Forty Sev­en co-founders, to tar­get new 'don't eat me' ...

4 years ago
Financing
Startups

Gami­da Cell gets IND cleared and clin­i­cal hold lift­ed, paving the way for PhI/II clin­i­cal tri­als

4 years ago
R&D

Catal­ent stays hot as it inks deal with French phar­ma that suf­fered PhI­II flop

4 years ago
Manufacturing

Pfiz­er and Val­neva's Ly­me dis­ease bet rolls on to PhI­II as more fi­nanc­ing flows their way

4 years ago
Financing
R&D

Covid-19 roundup: Biden looks to in­crease ac­cess to Pfiz­er's Paxlovid; House re­quests up­date from FDA on vac­cines for ...

4 years ago
Pharma
Coronavirus

Mar­tin Shkre­li fails to over­turn life­time phar­ma ban — again; Dai­ichi Sankyo and Vi­Gen­eron re-up eye dis­ease deal

4 years ago
News Briefing

In wake of IL-2 shut­down, Nek­tar lets go of 500+ staffers as it promis­es a turn­around

4 years ago
People
R&D

In a sur­prise move, No­var­tis CEO Vas Narasimhan re­cruits top an­a­lyst Ron­ny Gal as new strat­e­gy, BD chief

4 years ago
People

The End­points R&D 15: How many block­busters does $124B buy the biggest spenders in drug re­search? (Not enough)

4 years ago
Special
Pharma

Deer­field-backed biotech emerges from stealth with gene ther­a­py de­liv­ery plat­forms from Har­vard and MIT

4 years ago
Financing
Startups
First page Previous page 547548549550551552553 Next page Last page
A service from the Financial Times